Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Alzheimer’s Disease
Sort By
Newest First
1 / 2
Neurodegenerative Disease Clinical Trials
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
John Hamlet; Christine Martino, MPM; Sabine Krofczik-Wilhelm, Ph.D.; Alberto Lledó, M.D., Ph.D.
PPD, part of Thermo Fisher Scientific
PAO-09-022-CL-09
Sep 27, 2022
U.S. Food & Drug Administration
Alzheimer's Diagnostic Test
FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer's Disease
U.S. Food & Drug Administration
PR-M05-22-02
May 04, 2022
Column: New Drug Watch
Alzheimer Drug Still Controversial
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-022-NI-04
Mar 23, 2022
Araclon Biotech
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
Araclon Biotech
PR-M03-22-06
Mar 15, 2022
Alzheimer's Disease
Early Targeting of Chronic Inflammation That Precedes and Causes Synaptic Loss
Raymond J. Tesi, M.D.
INmune Bio
PTV-07-21-CL-001
Jul 29, 2021
Biogen
FDA Approval
FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease
Biogen
PR-M06-21-015
Jun 08, 2021
Stem Cells
Changing the Paradigm of Stem Cell Technology
Sandy Solmon
Celavie Biosciences
PAP-Q4-20-CL-008
Dec 09, 2020
Alzheimer's Disease
The Self-Protein Challenge
Andrea Pfeifer, Ph.D.
AC Immune
PAP-Q4-19-CL-002
Dec 06, 2019
Alzheimer's Disease
Innovating the Approach to Neurological Disease Treatment
Michaela Gallagher
AgeneBio
PAP-Q4-19-CL-004
Dec 06, 2019
T3D Therapeutics, Inc.
Funding
T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease
T3D Therapeutics, Inc.
PR-M11-19-NI-001
Nov 05, 2019
Prevention
Could Preventing the Development of Amyloid Beta Lesions in the Brain Stop Alzheimer’s?
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-19-NI-012
Sep 11, 2019
Pharma's Almanac
Research
New Alzheimer’s Test Could be on the Horizon
Pharma's Almanac
PAO-M08-19-NI-011
Aug 07, 2019
Eisai
Appointment
Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments
Eisai
PR-M05-19-NI-015
May 06, 2019
ProMIS Neurosciences
Research
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
ProMIS Neurosciences
PR-M03-19-NI-067
Mar 25, 2019
Machine Learning
Machine Learning May Benefit Future Alzheimer’s Patients
Emilie Branch
Pharma's Almanac
PAO-M03-19-NI-022
Mar 12, 2019
FDA
FDA Moves Against Companies Claiming Treatments for Alzheimer’s Disease
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M02-19-NI-013
Feb 19, 2019
ProMIS Neurosciences
Alzheimer's Disease
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
ProMIS Neurosciences
PR-M02-19-NI-001
Feb 04, 2019
Eisai
Alzheimer's Disease
First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials
Eisai
PR-M12-18-NI-037
Dec 12, 2018
Versant Health
Alzheimer's Disease
Ocular Technology Provides Early Detection of Alzheimer's Disease
Versant Health
PR-M12-18-NI-014
Dec 05, 2018
Research
Researchers Discover Potential Cause for Alzheimer’s Disease
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M11-18-NI-028
Nov 28, 2018
1 / 2
